{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:46:57Z","timestamp":1761983217832,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A critical aspect of drug development is evaluating pharmacokinetics (PK) and pharmacodynamics to assess how intrinsic (e.g., age, sex, comorbidities, and genomics) and extrinsic (e.g., drug\u2013drug interactions [DDIs] and food interaction) factors influence drug exposure and response. These aspects guide dose selection and inform drug labeling by accounting for interindividual variability to ensure safe and effective use across complex patient populations. However, identifying the relationship of co\u2010occurring factors, resembling complex patient populations, remains challenging. Herein, we analyzed drug labeling for therapeutic products approved by the Center of Drug Evaluation and Research at the US Food and Drug Administration from 2019 to 2023 to understand if intrinsic and extrinsic factors are considered simultaneously and how these factors influence prescribing recommendations. We characterized factors including pharmacogenomics (PGx), renal and hepatic function, age, pregnancy, body weight, comorbidities, and DDIs. Among 227 drug labelings, 93% independently assessed more than one factor and 2.6% evaluated the combined influence of two factors. Most drug labelings focused on single factors, with PK DDIs (70.0%), renal impairment (74.4%), and age (78.9%) frequently assessed. In rare disease indications, no significant differences in factor assessment frequency were observed. Of the six drug labelings that address simultaneously occurring factors, four addressed the interaction between PGx and PK DDIs. This analysis highlights a gap in evaluating co\u2010occurring intrinsic and extrinsic factors in drug labeling, underscoring the need for integrated approaches during drug development to better guide clinical decision making for complex patient populations.<\/jats:p>","DOI":"10.1002\/jcph.70064","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T22:28:13Z","timestamp":1750976893000},"page":"1392-1401","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA\u2010Approved Drugs"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-8950","authenticated-orcid":false,"given":"Samantha Lynn","family":"Bailey","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Therapeutics Center for Clinical Pharmaceutical Sciences University of Pittsburgh School of Pharmacy  Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-605X","authenticated-orcid":false,"given":"Sydney","family":"Stern","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Translational Science Office of Clinical Pharmacology US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyes","family":"Dahmane","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Translational Science Office of Clinical Pharmacology US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Ramamoorthy","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Translational Science Office of Clinical Pharmacology US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pacanowski","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Translational Science Office of Clinical Pharmacology US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schuck","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Translational Science Office of Clinical Pharmacology US Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"volume-title":"Manual of Policies and Procedures","year":"2023","author":"Center of Drug Evaluation and Research","key":"e_1_2_13_2_1"},{"key":"e_1_2_13_3_1","unstructured":"U.S. Food and Drug Administration.Guidance for Industry. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design Data Analysis and Impact on Dosing and Labeling; US Food and Drug Administration.2003.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010patients\u2010impaired\u2010hepatic\u2010function\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing\u2010and"},{"key":"e_1_2_13_4_1","unstructured":"U.S. Food and Drug Administration.Guidance for Industry. Pharmacokinetics in patients with impaired renal function \u2013 study design data analysis and impact on dosing.2024.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010patients\u2010impaired\u2010renal\u2010function\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing"},{"key":"e_1_2_13_5_1","unstructured":"U.S. Food and Drug Administration.Guidance for Industry. Pharmacokinetics in pregnancy \u2014 study design data analysis and impact on dosing and labeling.2004.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/pharmacokinetics\u2010pregnancy\u2010study\u2010design\u2010data\u2010analysis\u2010and\u2010impact\u2010dosing\u2010and\u2010labeling"},{"key":"e_1_2_13_6_1","unstructured":"U.S. Food and Drug Administration.Guidance for Industry. Clinical pharmacology considerations for peptide drug products.2023.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/clinical\u2010pharmacology\u2010considerations\u2010peptide\u2010drug\u2010products"},{"key":"e_1_2_13_7_1","unstructured":"U.S. Food and Drug Administration.Guidance for Industry. Clinical pharmacology considerations for antibody\u2010drug conjugates.2024.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/clinical\u2010pharmacology\u2010considerations\u2010antibody\u2010drug\u2010conjugates\u2010guidance\u2010industry"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01935"},{"key":"e_1_2_13_9_1","unstructured":"MAYZENT\u00ae (siponimod): Prescribing Information.2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209884s000lbl.pdf"},{"key":"e_1_2_13_10_1","unstructured":"CIBINQO\u00ae (abrocitinib): Prescribing Information.2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s001lbl.pdf"},{"key":"e_1_2_13_11_1","unstructured":"WAKIX\u00ae (pitolisant): Prescribing Information.2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211150s000lbl.pdf"},{"key":"e_1_2_13_12_1","unstructured":"TRODELVY\u00ae (sacituzumab govitecan\u2010hziy): Prescribing Information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf"},{"key":"e_1_2_13_13_1","unstructured":"WELIREG\u00ae(belzutifan): Prescribing Information.2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215383s000lbl.pdf"},{"key":"e_1_2_13_14_1","unstructured":"OLINVYK (oliceridine): Prescribing Information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210730s000lbl.pdf"},{"key":"e_1_2_13_15_1","unstructured":"BALVERSA (erdafitinib): Prescribing Information.2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212018s000lbl.pdf"},{"key":"e_1_2_13_16_1","unstructured":"ADUHELM\u2122 (aducanumab\u2010avwa): Prescribing Information.2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf"},{"key":"e_1_2_13_17_1","unstructured":"SOGROYA\u00ae (somapacitan\u2010beco): Prescribing Information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761156s000lbl.pdf"},{"key":"e_1_2_13_18_1","unstructured":"IMCIVREE (setmelanotide): Prescribing Information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213793Orig1s000RPLlbl.pdf"},{"key":"e_1_2_13_19_1","unstructured":"VELSIPITY\u2122 (etrasimod): Prescribing Information.2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216956s000lbl.pdf"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:43:13Z","timestamp":1761982993000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/jcph.70064"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70064","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}